Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6433
Gene Symbol: SFSWAP
SFSWAP
0.010 GeneticVariation group BEFREE They showed lower traits of the SWAP-200's cluster A and B disorders than SUD and PD patients, who presented more severe levels of personality impairment. 31281555 2019
Entrez Id: 9048
Gene Symbol: ARTN
ARTN
0.010 GeneticVariation group BEFREE Chronic pain and SUD had a negative impact on ART adherence. 31658202 2019
Entrez Id: 2247
Gene Symbol: FGF2
FGF2
0.010 AlteredExpression group BEFREE Thus, although additional studies are yet required, we suggest that reducing FGF2 activity may provide a novel therapeutic approach for substance use disorders. 30144335 2019
Entrez Id: 680
Gene Symbol: BRS3
BRS3
0.010 Biomarker group BEFREE G protein-coupled receptor heteromers are key players in substance use disorder. 30278192 2019
Entrez Id: 5640
Gene Symbol: PRS
PRS
0.010 Biomarker group BEFREE The association between PRS-ADHD and any SUD was slightly attenuated (OR = 1.21, 95% CI: 1.03-1.41) after adjusting for the other risk factors for SUD. 31803957 2019
Entrez Id: 3097
Gene Symbol: HIVEP2
HIVEP2
0.010 AlteredExpression group BEFREE Collectively, HIVEP2-mediated transcriptional mechanisms are implicated in dopaminergic pathophysiology of SUD. 31586043 2019
Entrez Id: 3034
Gene Symbol: HAL
HAL
0.010 Biomarker group BEFREE In comparison to the HAL class, psychotic and substance use disorders were more frequent in the DEL class, while anxiety and mood disorders were less frequent. 29232967 2018
Entrez Id: 140821
Gene Symbol: RSS
RSS
0.010 Biomarker group BEFREE While the review summarizes elements of D<sub>2</sub>RSS in schizophrenia per se, and its interplay with substance use disorder, a major focus is on presumed new molecular targets attending D<sub>2</sub>RSS in schizophrenia and related clinical entities. 29921706 2018
Entrez Id: 1137
Gene Symbol: CHRNA4
CHRNA4
0.010 Biomarker group BEFREE In this study, we investigated whether varenicline, a partial #4#2*nAChR agonist which reduces nicotine, alcohol and sucrose consumption, can reduce stress, a driving factor in substance use disorders. 29671814 2018
Entrez Id: 7971
Gene Symbol: GHS
GHS
0.010 AlteredExpression group BEFREE Besides the hypothalamus, ghrelin receptors (GHS-R1A) are also expressed in the mesolimbic dopaminergic system, which increases the possibility that ghrelin plays an important role in reward regulation for substance use disorders such as alcohol addiction, especially through activating the cholinergic-dopaminergic reward link. 28011402 2018
Entrez Id: 25928
Gene Symbol: SOSTDC1
SOSTDC1
0.010 AlteredExpression group BEFREE This project is optimizing Community Wise, an innovative multi-level behavioral-health intervention created in partnership with service providers and residents of distressed communities with histories of SUD and incarceration, to reduce health inequalities related to AIDU. 29703237 2018
Entrez Id: 1392
Gene Symbol: CRH
CRH
0.010 Biomarker group BEFREE The corticotropin-releasing factor (CRF) system mediates stress responses and might underlie substance use disorders; however, its involvement in social impairment induced by stimulant substances remains unknown. 29406581 2018
Entrez Id: 23237
Gene Symbol: ARC
ARC
0.010 GeneticVariation group BEFREE Repeated measurements of anxiety sensitivity and coping motives throughout treatment were examined from a randomized clinical trial comparing usual, CBT-based treatment at a substance use disorder specialty clinic (UC) to that usual care plus a brief CBT for anxiety program for patients with comorbid anxiety and substance use disorders (CALM ARC). 29852309 2018
Entrez Id: 574453
Gene Symbol: MIR495
MIR495
0.010 AlteredExpression group BEFREE Lentiviral-mediated miR-495 overexpression in the NAc shell (NAcsh) not only reversed these cocaine-induced effects but also downregulated multiple ARG mRNAs in specific SUD-related biological pathways, including those that regulate synaptic plasticity. miR-495 expression was also downregulated in the NAcsh of rats following cocaine self-administration. 28044061 2018
Entrez Id: 9914
Gene Symbol: ATP2C2
ATP2C2
0.010 Biomarker group BEFREE The significant association between age of initiation and ATP2C2 is consistent with the role of calcium signalling mechanisms in substance use disorders. 30003630 2018
Entrez Id: 9531
Gene Symbol: BAG3
BAG3
0.010 Biomarker group BEFREE One-hundred thirty-three obese individuals presenting for bariatric surgery (77.4% female) completed the BIS-15 and the Yale Food Addiction Scale (YFAS) 2.0, which measures addiction-like eating based on the eleven symptoms of substance use disorder outlined in the fifth version of the Diagnostic and Statistical Manual of Mental Disorders. 27768944 2017
Entrez Id: 3645
Gene Symbol: INSRR
INSRR
0.010 GeneticVariation group BEFREE We found dual diagnosis, defined as SUD concurring with other mental disorder, to be strongly associated with daytime primary health care utilization (IRR 11.0, 95% CI 5.9-20.6) when compared with those without any mental disorder diagnosis. 28637455 2017
Entrez Id: 2912
Gene Symbol: GRM2
GRM2
0.010 Biomarker group BEFREE From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. 27995279 2017
Entrez Id: 28954
Gene Symbol: REM1
REM1
0.010 Biomarker group BEFREE This paper compiles data about the causes and extent of REM/dream loss associated with commonly used medications, endemic substance use disorders, rampant sleep disorders, and behavioral and lifestyle factors. 28810072 2017
Entrez Id: 54820
Gene Symbol: NDE1
NDE1
0.010 Biomarker group BEFREE OAU+NDE patients were compared to non-OAU+NDE in terms of depression severity (PHQ-9 scores), incidence of PTSD, other anxiety disorders and substance use disorders after NDE, receipt of acute phase antidepressant treatment, dual antidepressant treatment, mood stabilizers and atypical antipsychotics. 28033519 2017
Entrez Id: 1269
Gene Symbol: CNR2
CNR2
0.010 Biomarker group BEFREE GWAS studies indicates that the CNR2 gene is associated with Parkinson's disease and substance use disorders. 29234141 2017
Entrez Id: 4803
Gene Symbol: NGF
NGF
0.010 Biomarker group BEFREE The nerve growth factor (NGF) and the vascular endothelial growth factor-A (VEGF-A) may be of importance for psychiatric diseases including substance use disorders. 29224006 2017
Entrez Id: 130497
Gene Symbol: OSR1
OSR1
0.010 Biomarker group BEFREE Meta-analysis showed a significantly increased risk for addiction in ADHD (n = 23, odds ratio [OR] 2.27, 95% CI 1.98-3.67; OR alcohol 2.15, 95% CI 1.56-2.97; OR drugs 1.52, 95% CI 1.52-5.27; OR nicotine 2.52, 95% CI 2.01-3.15; OR SUDs 2.61, 95% CI 1.77-3.84), ODD or CD (n = 8, OR 3.18, 95% CI 1.97-5.80; OR alcohol 1.73, 95% CI 1.51-2.00; OR drugs 4.24, 95% CI 1.3.21.5.59; OR nicotine 4.22, 95% CI 3.21-5.55; OR SUDs 4.86, 95% CI 3.09-7.56), and depression (n = 13, OR 2.03, 95% CI 1.47-2.81; OR alcohol 1.10, 95% CI 1.02-1.19; OR nicotine 2.56, 95% CI 1.89-3.48; OR SUDs 2.20, 95% CI 1.41-3.43), but not for anxiety disorders (n = 15, OR 1.34, 95% CI 0.90-1.55, not significant). 28647007 2017
Entrez Id: 2911
Gene Symbol: GRM1
GRM1
0.010 Biomarker group BEFREE mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together? 28285325 2017
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.010 Biomarker group BEFREE The nerve growth factor (NGF) and the vascular endothelial growth factor-A (VEGF-A) may be of importance for psychiatric diseases including substance use disorders. 29224006 2017